ForSight Vision 5 Report issue

For profit Phase 2
Founded: Menlo Park CA United States (2010)
Status: Acquired by Allergan PLC (2015) (2016) → now AbbVie (2019)

Organization Overview

First Clinical Trial
2013
NCT01915940
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ForSight VISION5 | ForSight VISION 5 | ForSight Vision5, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

bimatoprost (lumigan) (7 trials)

timolol (blocadren) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glaucoma (Phase 2)

Glaucoma, Open-Angle (Phase 2)

Hypertension (Phase 2)

Ocular Hypertension (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 2